NDC 0067-2039

EXCEDRIN MIGRAINE

Acetaminophen, Aspirin (nsaid) And Caffeine

EXCEDRIN MIGRAINE is a Oral Tablet, Film Coated in the Human Otc Drug category. It is labeled and distributed by Glaxosmithkline Consumer Healthcare Holdings (us) Llc. The primary component is Acetaminophen; Aspirin; Caffeine.

Product ID0067-2039_34dc47b2-41d4-49ae-abb0-80d04ef55dca
NDC0067-2039
Product TypeHuman Otc Drug
Proprietary NameEXCEDRIN MIGRAINE
Generic NameAcetaminophen, Aspirin (nsaid) And Caffeine
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2010-02-15
Marketing CategoryNDA / NDA
Application NumberNDA020802
Labeler NameGlaxoSmithKline Consumer Healthcare Holdings (US) LLC
Substance NameACETAMINOPHEN; ASPIRIN; CAFFEINE
Active Ingredient Strength250 mg/1; mg/1; mg/1
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 0067-2039-02

2 TABLET, FILM COATED in 1 POUCH (0067-2039-02)
Marketing Start Date2010-02-15
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0067-2039-50 [00067203950]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Billing UnitEA
Marketing Start Date2010-02-15

NDC 0067-2039-02 [00067203902]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Marketing Start Date2010-02-15

NDC 0067-2039-08 [00067203908]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Billing UnitEA
Marketing Start Date2010-02-15
Marketing End Date2014-12-31

NDC 0067-2039-33 [00067203933]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Billing UnitEA
Marketing Start Date2010-02-15

NDC 0067-2039-24 [00067203924]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Billing UnitEA
Marketing Start Date2010-02-15

NDC 0067-2039-83 [00067203983]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Marketing Start Date2010-02-15

NDC 0067-2039-77 [00067203977]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Billing UnitEA
Marketing Start Date2010-02-15

NDC 0067-2039-91 [00067203991]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Billing UnitEA
Marketing Start Date2010-02-15

NDC 0067-2039-94 [00067203994]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Marketing Start Date2010-02-15
Marketing End Date2012-12-31

NDC 0067-2039-09 [00067203909]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Marketing Start Date2010-02-15
Marketing End Date2017-07-31

NDC 0067-2039-30 [00067203930]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Marketing Start Date2010-02-15

NDC 0067-2039-84 [00067203984]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Marketing Start Date2010-02-15
Marketing End Date2014-07-31

NDC 0067-2039-92 [00067203992]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Billing UnitEA
Marketing Start Date2010-02-15

NDC 0067-2039-86 [00067203986]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Billing UnitEA
Marketing Start Date2010-02-15
Marketing End Date2014-12-31

NDC 0067-2039-07 [00067203907]

EXCEDRIN MIGRAINE TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA020802
Product TypeHUMAN OTC DRUG
Marketing Start Date2010-02-15
Marketing End Date2012-12-31

Drug Details

Active Ingredients

IngredientStrength
ACETAMINOPHEN250 mg/1

OpenFDA Data

SPL SET ID:7ed841fb-a61c-4868-b4e5-4f2311a5e79c
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 308297
  • 209468
  • Pharm Class PE
  • Decreased Prostaglandin Production [PE]
  • Decreased Platelet Aggregation [PE]
  • PHarm Class EPC
  • Nonsteroidal Anti-inflammatory Drug [EPC]
  • Platelet Aggregation Inhibitor [EPC]
  • NUI Code
  • N0000008832
  • N0000008836
  • N0000175721
  • N0000000160
  • N0000175578
  • N0000175722
  • NDC Crossover Matching brand name "EXCEDRIN MIGRAINE" or generic name "Acetaminophen, Aspirin (nsaid) And Caffeine"

    NDCBrand NameGeneric Name
    52904-871Excedrin Migraineacetaminophen, aspirin, and caffeine
    66715-9749Excedrin Migraineacetaminophen, aspirin, and caffeine
    0067-2040Excedrin MigraineExcedrin Migraine
    0067-2039EXCEDRINAcetaminophen, Aspirin (NSAID) and Caffeine
    0067-8201EXCEDRINAcetaminophen, Aspirin (NSAID) and Caffeine
    53808-0835EXCEDRINAcetaminophen, Aspirin (NSAID) and Caffeine
    67414-239EXCEDRINAcetaminophen, Aspirin (NSAID) and Caffeine

    Trademark Results [EXCEDRIN]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    EXCEDRIN
    EXCEDRIN
    97425413 not registered Live/Pending
    GSK Consumer Healthcare SARL
    2022-05-24
    EXCEDRIN
    EXCEDRIN
    97210682 not registered Live/Pending
    GSK Consumer Healthcare SARL
    2022-01-10
    EXCEDRIN
    EXCEDRIN
    97210676 not registered Live/Pending
    GSK Consumer Healthcare SARL
    2022-01-10
    EXCEDRIN
    EXCEDRIN
    86434099 4978864 Live/Registered
    GSK CONSUMER HEALTHCARE S.A.
    2014-10-24
    EXCEDRIN
    EXCEDRIN
    85243455 3985911 Live/Registered
    GSK CONSUMER HEALTHCARE S.A.
    2011-02-16
    EXCEDRIN
    EXCEDRIN
    74504161 1892912 Dead/Cancelled
    Bristol-Myers Squibb Company
    1994-03-23
    EXCEDRIN
    EXCEDRIN
    73661685 1472811 Dead/Cancelled
    BRISTOL-MYERS COMPANY
    1987-05-18
    EXCEDRIN
    EXCEDRIN
    72080162 0696323 Dead/Cancelled
    BRISTOL-MYERS COMPANY
    1959-08-25

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.